← All trials
NCT06186154
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2024
- Primary completion
- Jan 31, 2025
- Completion date
- Mar 31, 2025
- First posted
- Dec 29, 2023
- Last posted
- Dec 29, 2023
- Enrollment
- 25
- Arms / groups
- — / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of British ColumbiaLead sponsor
- University of British ColumbiaReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.